| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
2-[[3-(4-Morpholinyl)propyl]amino]-4-pyridinecarboxylic acid 2-[1-(4-chloro-2-hydroxyphenyl)propylidene]hydrazide manufacturers
- M-110
-
- $58.00
-
2026-07-14
- CAS:1395048-49-3
- Purity: 99.55%
- Supply Ability: 10g
|
| | 2-[[3-(4-Morpholinyl)propyl]amino]-4-pyridinecarboxylic acid 2-[1-(4-chloro-2-hydroxyphenyl)propylidene]hydrazide Basic information |
| | 2-[[3-(4-Morpholinyl)propyl]amino]-4-pyridinecarboxylic acid 2-[1-(4-chloro-2-hydroxyphenyl)propylidene]hydrazide Chemical Properties |
| density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble25mg/mL, clear | | pka | 7.46±0.40(Predicted) | | form | powder | | color | white to beige |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | 2-[[3-(4-Morpholinyl)propyl]amino]-4-pyridinecarboxylic acid 2-[1-(4-chloro-2-hydroxyphenyl)propylidene]hydrazide Usage And Synthesis |
| Uses | M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC50=47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC50s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC50s of 0.6 to 0.9 μM[1]. | | Biochem/physiol Actions | M-110 is a highly isoform-selective, cell permeable and potent ATP-competitive inhibitor of the PIM kinase family that prefers PIM-3. M-110 is an inhibitor of Wnt/β-catenin signaling that act downstream of the symb-catenin destruction complex to inhibit both Wnt-induced and cancer associated constitutive Wnt signaling via destabilization of β-catenin. The compound chelates iron in vitro and in intact cells. M-110 inhibits the proliferation of prostate cancer cell lines with IC50s of 0.6 to 0.9 μM, with no activity on normal human peripheral blood mononuclear cells up to 40 μM. | | References | [1] Chang M, et al.PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.MolCancerTher.2010 Sep;9(9):2478-87. DOI:10.1158/1535-7163.MCT-10-0321
[2] He Y, et al. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways. Biochem Biophys Res Commun. 2014 Jul 4;449(3):344-50. DOI:10.1016/j.bbrc.2014.05.034
[3] Zhou E, et al. Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways. Int Immunopharmacol. 2014 Sep;22(1):133-40. DOI:10.1016/j.intimp.2014.06.004
[4] Sa F, et al. Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo. Neurosci Lett. 2015 Apr 23;593:7-12. DOI:10.1016/j.neulet.2015.03.016
[5] Zhang LQ, et al. Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and AKT/GSK3β pathways. J Ethnopharmacol. 2015 Apr 29. pii: S0378-8741(15)00306-2. DOI:10.1016/j.jep.2015.04.040 |
| | 2-[[3-(4-Morpholinyl)propyl]amino]-4-pyridinecarboxylic acid 2-[1-(4-chloro-2-hydroxyphenyl)propylidene]hydrazide Preparation Products And Raw materials |
|